Abstract
Purpose Patients with Fanconi anaemia (FA), a rare DNA repair genetic disease, exhibit chromosome fragility, bone marrow failure, malformations and cancer susceptibility. FA molecular diagnosis is challenging since FA is caused by point mutations and large deletions in 22 genes following three heritability patterns. To optimise FA patients' characterisation, we developed a simplified but effective methodology based on whole exome sequencing (WES) and functional studies. Methods 68 patients with FA were analysed by commercial WES services. Copy number variations were evaluated by sequencing data analysis with RStudio. To test FANCA missense variants, wt FANCA cDNA was cloned and variants were introduced by site-directed mutagenesis. Vectors were then tested for their ability to complement DNA repair defects of a FANCA-KO human cell line generated by TALEN technologies. Results We identified 93.3% of mutated alleles including large deletions. We determined the pathogenicity of three FANCA missense variants and demonstrated that two FANCA variants reported in mutations databases as € affecting functions' are SNPs. Deep analysis of sequencing data revealed patients' true mutations, highlighting the importance of functional analysis. In one patient, no pathogenic variant could be identified in any of the 22 known FA genes, and in seven patients, only one deleterious variant could be identified (three patients each with FANCA and FANCD2 and one patient with FANCE mutations) Conclusion WES and proper bioinformatics analysis are sufficient to effectively characterise patients with FA regardless of the rarity of their complementation group, type of mutations, mosaic condition and DNA source.
Original language | English |
---|---|
Pages (from-to) | 258-268 |
Number of pages | 11 |
Journal | Journal of medical genetics |
Volume | 57 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Apr 2020 |
Keywords
- clinical genetics
- genetics
- haematology (incl blood transfusion)
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. / Bogliolo, Massimo; Pujol, Roser; Aza-Carmona, Miriam; Muñoz-Subirana, Núria; Rodriguez-Santiago, Benjamin; Casado, José Antonio; Rio, Paula; Bauser, Christopher; Reina-Castillón, Judith; Lopez-Sanchez, Marcos; Gonzalez-Quereda, Lidia; Gallano, Pia; Catalá, Albert; Ruiz-Llobet, Ana; Badell, Isabel; DIaz-Heredia, Cristina; Hladun, Raquel; Senent, Leonort; Argiles, Bienvenida; Bergua Burgues, Juan Miguel; Bañez, Fatima; Arrizabalaga, Beatriz; López Almaraz, Ricardo; Lopez, Monica; Figuera, Ángela; Molinés, Antonio; Pérez De Soto, Inmaculada; Hernando, Inés; Muñoz, Juan Antonio; Del Rosario Marin, Maria; Balmaña, Judith; Stjepanovic, Neda; Carrasco, Estela; Cuesta, Isabel; Cosuelo, José Miguel; Regueiro, Alexandra; Moraleda Jimenez, José; Galera-Miñarro, Ana Maria; Rosiñol, Laura; Carrió, Anna; Beléndez-Bieler, Cristina; Escudero Soto, Antonio; Cela, Elena; De La Mata, Gregorio; Fernández-Delgado, Rafael; Garcia-Pardos, Maria Carmen; Sáez-Villaverde, Raquel; Barragaño, Marta; Portugal, Raquel; Lendinez, Francisco; Hernadez, Ines; Vagace, José Manue; Tapia, Maria; Nieto, José; Garcia, Marta; Gonzalez, MacArena; Vicho, Cristina; Galvez, Eva; Valiente, Alberto; Antelo, Maria Luisa; Ancliff, Phil; Garcia, Francisco; Dopazo, Joaquin; Sevilla, Julian; Paprotka, Tobias; Pérez-Jurado, Luis Alberto; Bueren, Juan; Surralles, Jordi.
In: Journal of medical genetics, Vol. 57, No. 4, 01.04.2020, p. 258-268.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies
AU - Bogliolo, Massimo
AU - Pujol, Roser
AU - Aza-Carmona, Miriam
AU - Muñoz-Subirana, Núria
AU - Rodriguez-Santiago, Benjamin
AU - Casado, José Antonio
AU - Rio, Paula
AU - Bauser, Christopher
AU - Reina-Castillón, Judith
AU - Lopez-Sanchez, Marcos
AU - Gonzalez-Quereda, Lidia
AU - Gallano, Pia
AU - Catalá, Albert
AU - Ruiz-Llobet, Ana
AU - Badell, Isabel
AU - DIaz-Heredia, Cristina
AU - Hladun, Raquel
AU - Senent, Leonort
AU - Argiles, Bienvenida
AU - Bergua Burgues, Juan Miguel
AU - Bañez, Fatima
AU - Arrizabalaga, Beatriz
AU - López Almaraz, Ricardo
AU - Lopez, Monica
AU - Figuera, Ángela
AU - Molinés, Antonio
AU - Pérez De Soto, Inmaculada
AU - Hernando, Inés
AU - Muñoz, Juan Antonio
AU - Del Rosario Marin, Maria
AU - Balmaña, Judith
AU - Stjepanovic, Neda
AU - Carrasco, Estela
AU - Cuesta, Isabel
AU - Cosuelo, José Miguel
AU - Regueiro, Alexandra
AU - Moraleda Jimenez, José
AU - Galera-Miñarro, Ana Maria
AU - Rosiñol, Laura
AU - Carrió, Anna
AU - Beléndez-Bieler, Cristina
AU - Escudero Soto, Antonio
AU - Cela, Elena
AU - De La Mata, Gregorio
AU - Fernández-Delgado, Rafael
AU - Garcia-Pardos, Maria Carmen
AU - Sáez-Villaverde, Raquel
AU - Barragaño, Marta
AU - Portugal, Raquel
AU - Lendinez, Francisco
AU - Hernadez, Ines
AU - Vagace, José Manue
AU - Tapia, Maria
AU - Nieto, José
AU - Garcia, Marta
AU - Gonzalez, MacArena
AU - Vicho, Cristina
AU - Galvez, Eva
AU - Valiente, Alberto
AU - Antelo, Maria Luisa
AU - Ancliff, Phil
AU - Garcia, Francisco
AU - Dopazo, Joaquin
AU - Sevilla, Julian
AU - Paprotka, Tobias
AU - Pérez-Jurado, Luis Alberto
AU - Bueren, Juan
AU - Surralles, Jordi
N1 - Funding Information: 1Department of genetics and Microbiology, Universitat autonoma de Barcelona, Barcelona, spain 2hospital Universitario la Paz, Madrid, spain 3hospital de la santa creu i sant Pau institut de recerca, Barcelona, spain 4cieMaT, Madrid, spain 5eurofins gaTc Biotech gmbh, Konstanz, germany 6hospital del Mar research institute (iMiM), Universitat Pompeu Fabra, Barcelona, spain 7Department of genetics, hospital de la santa creu i sant Pau, Universitat autónoma de Barcelona (UaB), Barcelona, spain 8Department of hematology, hospital sant Joan de Déu, Barcelona, spain 9Pediatric hematology and Oncology Department, hospital sant Joan de Deu, Barcelona, spain 10Pediatric hematology and hscT Unit, hospital de la santa creu i sant Pau, Barcelona, spain 11hospital Universitari Vall d’hebron (hUVh), Vall d’hebron research institute (Vhir), Barcelona, spain 12hospital Vall d’hebron, Barcelona, spain 13hospital la Fe, Valencia, spain 14Pediatric haematology Unit, hospital de la Fe, Valencia, spain 15hospital san Pedro de alcántara, caceres, spain 16hospital de cruces, Barakaldo, spain 17hospital Universitario Marques de Valdecilla, santander, spain 18hospital Universitario de la Princesa, Madrid, spain 19c.h.U. insular-Materno infantil, las Palmas de gran canaria, spain 20hospital Universitario Virgen del rocío, sevilla, spain 21hospital Universitario central de asturias, Oviedo, spain 22hospital Universitario Puerta del Mar, cadiz, spain 23Medical Oncology Department, University hospital Vall d’hebron, Barcelona, spain 24Medical Oncology Department, hospital Vall d’hebron, Barcelona, spain 25high risk and cancer Prevention group, Vall d’hebron institut d’Oncologia, Barcelona, spain 26hereditary cancer Unit, Vall d’hebron institut d’Oncologia, Barcelona, spain 27hospital general de Teruel Obispo Polanco, Teruel, spain 28hospital clinico Universitario de santiago de compostela, santiago de compostela, spain 29hospital Virgen de la arrixaca, el Palmar, spain 30hospital clinico Universitario Virgen de la arrixaca, el Palmar, spain 31hospital clínic de Barcelona, Barcelona, spain 32Pediatric Oncology and hematology section, general University hospital gregorio Marañón, Madrid, spain 33hospital Universitario de Burgos, Burgos, spain 34hospital clínico Universitario, Valencia, spain 35hospital of Donostia, san sebastian, spain 36Department of genetics, hospital Universitario Donostia, gipuzkoa, spain 37san rafael hospital, Madrid, spain 38hospital Universitario Torrecárdenas, almeria, spain 39hospital germans Trias i Pujol, Badalona, spain 40hospital Materno infantil de Badajoz, Badajoz, spain 41hospital general de la Palma, Brena alta, spain 42hospital general Universitario José M Morales Meseguer, Murcia, spain 43hospital Mutua de Terrassa, Terrassa, spain 44hospital Universitario de canarias, la laguna, spain 45hospital infantil Universitario nino Jesus, Madrid, spain 46complejo hospitalario de navarra, Pamplona, spain 47great Ormond street hospital for children, london, UK 48computational genomics Department, centro de investigación Príncipe Felipe, Valencia, spain 49Fundación Pública andaluza Progreso y salud, sevilla, spain 50Unitat de genètica, Universitat Pompeu Fabra, Barcelona, spain Contributors MasB: planned and coordinated the study, performed experiments, analysed the data and wrote the manuscript. roP: performed experiments and coordinated the study. Ma-c, ns, Jac and Pr: performed experiments. Br-s, Fg and JD: bioinformatics data analysis. cB and TP: coordinated the study. Jr-c: performed experiments, bioinformatics data analysis. Ml-s: performed experiments and bioinformatics data analysis. lg-Q and Pg: analysed the data. aic, ar-l, iB, cD-h, rh, ls, Ba, JMBB, Fi, Ba, Ml, ÁF, aM, iPds, inésh, JaM, MdrM, JudB, ns, ec, ic, JMc, ar, JMJ, aMg-M, lr, anc, cB-B, aes, esc, gdiM, rF-D, Mcg-P, rs-V, MarB, raP, Fl, inesh, JMV, MT, Jn, Marg, Macg, cV, eg, aV, Mla and Pa: provided patients samples and clinical data. Jus: coordinated the study and analysed data. laP-J: analysed data and corrected the manuscript. JuaB: coordinated the study and corrected the manuscript. Jos: planned and coordinated the study, provided funding and corrected the manuscript. all the authors read and approved the manuscript. MasB and Jos are guarantors for the overall content of the manuscript Funding surrallés laboratory is supported by icrea-academia programme, spanish Ministry of health (projects FancOsTeM and FancOlen), spanish Ministry of economy and competiveness (projects cB06/07/0023 and saF2015-64152-r), european commission (eUrOFancOlen project healTh-F5-2012-305421 and P-sPhere cOFUnD project), Fanconi anemia research Fund inc and the ’Fondo europeo de Desarrollo regional, una manera de hacer europa’ (FeDer). This work was also funded by intramural actions (acci-U735/U745-2016 to laPJ and Js) of ciBerer. ciBerer is an initiative of the instituto de salud carlos iii, spain.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose Patients with Fanconi anaemia (FA), a rare DNA repair genetic disease, exhibit chromosome fragility, bone marrow failure, malformations and cancer susceptibility. FA molecular diagnosis is challenging since FA is caused by point mutations and large deletions in 22 genes following three heritability patterns. To optimise FA patients' characterisation, we developed a simplified but effective methodology based on whole exome sequencing (WES) and functional studies. Methods 68 patients with FA were analysed by commercial WES services. Copy number variations were evaluated by sequencing data analysis with RStudio. To test FANCA missense variants, wt FANCA cDNA was cloned and variants were introduced by site-directed mutagenesis. Vectors were then tested for their ability to complement DNA repair defects of a FANCA-KO human cell line generated by TALEN technologies. Results We identified 93.3% of mutated alleles including large deletions. We determined the pathogenicity of three FANCA missense variants and demonstrated that two FANCA variants reported in mutations databases as € affecting functions' are SNPs. Deep analysis of sequencing data revealed patients' true mutations, highlighting the importance of functional analysis. In one patient, no pathogenic variant could be identified in any of the 22 known FA genes, and in seven patients, only one deleterious variant could be identified (three patients each with FANCA and FANCD2 and one patient with FANCE mutations) Conclusion WES and proper bioinformatics analysis are sufficient to effectively characterise patients with FA regardless of the rarity of their complementation group, type of mutations, mosaic condition and DNA source.
AB - Purpose Patients with Fanconi anaemia (FA), a rare DNA repair genetic disease, exhibit chromosome fragility, bone marrow failure, malformations and cancer susceptibility. FA molecular diagnosis is challenging since FA is caused by point mutations and large deletions in 22 genes following three heritability patterns. To optimise FA patients' characterisation, we developed a simplified but effective methodology based on whole exome sequencing (WES) and functional studies. Methods 68 patients with FA were analysed by commercial WES services. Copy number variations were evaluated by sequencing data analysis with RStudio. To test FANCA missense variants, wt FANCA cDNA was cloned and variants were introduced by site-directed mutagenesis. Vectors were then tested for their ability to complement DNA repair defects of a FANCA-KO human cell line generated by TALEN technologies. Results We identified 93.3% of mutated alleles including large deletions. We determined the pathogenicity of three FANCA missense variants and demonstrated that two FANCA variants reported in mutations databases as € affecting functions' are SNPs. Deep analysis of sequencing data revealed patients' true mutations, highlighting the importance of functional analysis. In one patient, no pathogenic variant could be identified in any of the 22 known FA genes, and in seven patients, only one deleterious variant could be identified (three patients each with FANCA and FANCD2 and one patient with FANCE mutations) Conclusion WES and proper bioinformatics analysis are sufficient to effectively characterise patients with FA regardless of the rarity of their complementation group, type of mutations, mosaic condition and DNA source.
KW - clinical genetics
KW - genetics
KW - haematology (incl blood transfusion)
UR - http://www.scopus.com/inward/record.url?scp=85073172364&partnerID=8YFLogxK
U2 - 10.1136/jmedgenet-2019-106249
DO - 10.1136/jmedgenet-2019-106249
M3 - Article
C2 - 31586946
AN - SCOPUS:85073172364
VL - 57
SP - 258
EP - 268
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
SN - 0022-2593
IS - 4
ER -